Head-to-head · WeighScore
Aspen vs TeleCareSpot
The verdict
TeleCareSpot takes it — 67.7/100 to 58.4/100.
TeleCareSpot grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Aspen | TeleCareSpot |
|---|---|---|
| WeighScore | 58.4/100 | 67.7/100 |
| Grade | C | C |
| Scorecard rank | #373 | #163 |
| Semaglutide | $279/mo (3-month plan, compounded) | $299/mo (all doses, plus a separate fee, compounded) |
| Tirzepatide | $399/mo (compounded) | $399/mo |
| Coverage | All 50 states | 48 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #373 · C
Strengths
- LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
- Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
- Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
- Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
- Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC
Where it loses points
- Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
- Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
- The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
- Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit
Graded #163 · C
Strengths
- Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
- Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
- Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
- DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
- Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans
Where it loses points
- Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Not available in Alaska, Mississippi, or New Jersey
- The compounding pharmacy partner is not named
- A separate weight-loss consultation fee applies (credited toward your medication package if approved)
- Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.